Diabetes Mellitus, Type 2 Clinical Trial
Official title:
An Objective Assessment of Mealtime Bolus Insulin Behavior and Associated Factors
Verified date | July 2018 |
Source | Eli Lilly and Company |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The main purpose of this study is to estimate missed bolus insulin doses in diabetics. This is a 12-week, single-arm, outpatient, exploratory study with two study periods in Type 1 or Type 2 diabetics, with an investigational reusable injection pen, insulin, and a Continuous Glucose Monitoring (CGM) device.
Status | Completed |
Enrollment | 79 |
Est. completion date | July 23, 2018 |
Est. primary completion date | June 12, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 21 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Have a Type 1 Diabetes Mellitus (T1D) or a Type 2 Diabetes Mellitus (T2D) diagnosis - Must be taking a mealtime bolus dose insulin, greater than or equal to (=) 3 doses - Each individual bolus insulin dose must be less than (<) 40 units - Must be taking a stable insulin dose regimen for the last 3 months - Must be taking a bolus insulin analog (for example insulin lispro [U-100]/[U-200], insulin aspart, or insulin glulisine). In addition, must be able to switch to insulin lispro U-100 for the duration of the trial - Must have a hemoglobin A1c (HbA1c) =8.0% in the last 6 months - Participants with T1D must be =21 to less than or equal to (=) 65 years of age. Participants with T2D must be =35 to =65 years of age - Women of childbearing potential must meet the following: (Note: females of childbearing potential are defined as those who have experienced menarche and who are NOT permanently sterile or postmenopausal. Postmenopausal is defined as 12 consecutive months with no menses without an alternative medical cause) - Must agree to use 1 highly effective method of contraception, or a combination of 2 effective methods of contraception for the entirety of the study - Must test negative for pregnancy as indicated by a negative serum or urine pregnancy test - Participants with prior CGM/flash glucose monitoring experience must have stopped CGM/flash glucose monitoring =3 months prior to enrollment Exclusion Criteria: - Have known tape/adhesive allergies with CGM sensors - Medical conditions, visual, physical, psychiatric, or cognitive impairment(s) that may preclude the ability to participate in the trial - Have history of liver disease, acute or chronic hepatitis, or alanine aminotransferase or aspartate aminotransferase levels =3 times the upper limit of the reference range within the last 6 months - Have history of chronic kidney disease stage 4 and higher within the last 6 months, or history of renal transplantation - Have active malignancy - Are pregnant or planning to become pregnant - Are on or are intending to begin a weight loss program - Participants with T1D who have taken off-label antihyperglycemic agents within last 3 months - Have received insulin by continuous subcutaneous insulin infusion in the last 3 months - Participants taking opioid medications for medically invalid reasons or at doses considered excessive - Participants on routine use of acetaminophen - Currently undergoing systemic treatment with: - Immunosuppressive medication - Chronic (lasting longer than 2 weeks) systemic glucocorticoid therapy (excluding topical and inhaled preparations) or have received such therapy within the prior 2 weeks - Are currently enrolled in any other clinical study involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study - Have participated, within the last 30 days, in a clinical study involving an investigational product - Are unwilling or unable to comply with the use of a data collection device to directly record data |
Country | Name | City | State |
---|---|---|---|
United States | AMCR Institute, Inc. | Escondido | California |
United States | Rocky Mountain Diabetes and Osteoporosis Center | Idaho Falls | Idaho |
United States | Science 37 Inc | Los Angeles | California |
United States | Advanced Research Institute | Ogden | Utah |
United States | Coastal Metabolic Research Ctr | Ventura | California |
United States | Iowa Diabetes & Endocrinology Research Center | West Des Moines | Iowa |
Lead Sponsor | Collaborator |
---|---|
Eli Lilly and Company |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Average Number of Days Per Month With a Missed Bolus Insulin Dose With Blinded CGM | The average number of days per month with a missed bolus insulin dose was calculated in participants with Type 1 Diabetes or Type 2 Diabetes using blinded CGM measurements and the pen. The time of insulin dosing and glucose excursions were assessed using the display times recorded by the pen and CGM devices, respectively. | Week 1 up to 6 weeks | |
Secondary | Average Number of Days Per Month With a Missed Bolus Insulin Dose With Unblinded CGM | The average number of days per month with a missed bolus insulin dose was calculated in participants with Type 1 Diabetes or Type 2 Diabetes using unblinded CGM measurements and the pen. The time of insulin dosing and glucose excursions were assessed using the display times recorded by the pen and CGM devices, respectively | Week 6 up to 12 weeks | |
Secondary | Percentage of Time-in-Range (Glucose >70 and =180 Milligrams Per Deciliter) With Blinded CGM | Percentage of time-in-range (glucose >70 and =180 milligrams per deciliter) was calculated in participants with Type 1 Diabetes or Type 2 Diabetes based on blinded CGM data collected in the study period. The time component of the time-in-range statistic was calculated using the display time recorded by the CGM device. | Baseline up to 6 weeks | |
Secondary | Percentage of Time-in-Range (Glucose >70 and =180 Milligrams Per Deciliter) With Unblinded CGM | Percentage of time-in-range (glucose >70 and =180 milligrams per deciliter) was calculated in participants with Type 1 Diabetes or Type 2 Diabetes based on unblinded CGM data collected in the study period. The time component of the time-in-range statistic was calculated using the display time recorded by the CGM device. | Week 6 up to 12 weeks | |
Secondary | Percentage of Missed Bolus Doses Per Month With Blinded CGM | Percentage of missed bolus doses per month was estimated in participants with Type 1 diabetes or Type 2 diabetes using blinded CGM measurements and the pen. | Baseline up to 6 weeks | |
Secondary | Percentage of Missed Bolus Doses Per Month With Unblinded CGM | Percentage of missed bolus doses per month was estimated in participants with Type 1 diabetes or Type 2 diabetes using unblinded CGM measurements and the pen. | Week 6 up to 12 weeks | |
Secondary | Average Number of Missed Bolus Insulin Doses Per Day With Blinded CGM | The average number of missed bolus doses per day was estimated in participants with Type 1 diabetes or Type 2 diabetes using blinded CGM measurements and the pen. | Baseline up to 6 weeks | |
Secondary | Average Number of Missed Bolus Insulin Doses Per Day With Unblinded CGM | The average number of missed bolus doses per day was estimated in participants with Type 1 diabetes or Type 2 diabetes using unblinded CGM data. | Week 6 up to 12 weeks | |
Secondary | Average Number of Missed and Suboptimal Bolus Dose (MSBD) Events Per Month With Blinded CGM | The number of Missed and Suboptimal Doses (MSBDs) per month was calculated in participants with Type 1 Diabetes or Type 2 Diabetes as the sum of the identified missed bolus doses and suboptimal bolus doses for each participant for each period. | Baseline up to 6 weeks | |
Secondary | Average Number of Missed and Suboptimal Bolus Dose (MSBD) Events Per Month With Unblinded CGM | The number of Missed and Suboptimal Doses (MSBDs) per month was calculated in participants with Type 1 Diabetes or Type 2 Diabetes as the sum of the identified missed bolus doses and suboptimal bolus doses for each participant for each period. | Week 6 up to 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05666479 -
CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
|
||
Completed |
NCT05647083 -
The Effect of Massage on Diabetic Parameters
|
N/A | |
Active, not recruiting |
NCT05661799 -
Persistence of Physical Activity in People With Type 2 Diabetes Over Time.
|
N/A | |
Completed |
NCT03686722 -
Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin
|
Phase 1 | |
Completed |
NCT02836704 -
Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose)
|
Phase 4 | |
Completed |
NCT01819129 -
Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes
|
Phase 3 | |
Completed |
NCT04562714 -
Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy
|
N/A | |
Completed |
NCT02009488 -
Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
Completed |
NCT05896319 -
Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2
|
N/A | |
Recruiting |
NCT05598203 -
Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes
|
N/A | |
Completed |
NCT05046873 -
A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People
|
Phase 1 | |
Terminated |
NCT04090242 -
Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes
|
N/A | |
Completed |
NCT04030091 -
Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus
|
Phase 4 | |
Completed |
NCT03604224 -
A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
|
||
Completed |
NCT03620357 -
Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D)
|
N/A | |
Completed |
NCT01696266 -
An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
|
||
Completed |
NCT03620890 -
Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy
|
Phase 4 | |
Withdrawn |
NCT05473286 -
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
|
||
Not yet recruiting |
NCT05029804 -
Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes
|
N/A | |
Completed |
NCT04531631 -
Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes
|
Phase 2 |